본문 바로가기 주메뉴 바로가기

NEWS


[October 25, 2018] Investment in A Japanese Biotech Company (Series A)

BiGEN invested on A Japanese biotech company, a regenerative medicine company, located in Tokyo, Japan.

This company is a spin-off company from A Japanese University.  In the IIT conducted by the Japanese University, the autologous Treg-enriched cells manufactured by co-culturing them with irradiated donor T cells and antibodies were infused to the patients who have undergone liver transplants, and 7 out of 10 patients showed ‘operational tolerance’ under the condition of discontinuing or reducing immunosuppressants